and Dr F C Greenwood (Imperial Cancer Research Fund Laboratories, London) Radioactive Implants of the Pituitary for Endocrine Disease Two nuclides, yttrium 90 and gold 198, are currently used by us for transnasal implantation into the pituitary fossa. Yttrium 90 (9OY), a beta emitter, is implanted with the aim of achieving complete destruction of the pituitary gland, a procedure used predominantly to treat patients with advanced cancer of the breast. The results of pituitary function studies and of histological examination of the pituitary post mortem (Forrest & Stewart 1970) suggest that complete ablation of the normal pituitary is achieved in only about three-quarters of patients.
Gold 198 (19"Au), which emits gamma rays, is used to deliver a suppressing dose of radiation to the gland. The activity of the seeds is planned to deliver not more than 10,000 rads to the roof of the pituitary fossa.
The implantation of both these nuclides has been used for the treatment of acromegaly and of "'lAu for Cushing's syndrome of pituitary type.
Acromegaly
The clinical features of acromegaly are widely recognized but it is insufficiently recognized that these patients frequently are distressed, not only by their grotesque appearance, but by headache,.sweating, acne, carpal tunnel syndrome and diabetes. Further, their life span may be compromised by cardiovascular complications. Although conventional pituitary surgery is seldom advocated unless vision is threatened, we believe that, provided plasma growth levels are excessive, their pituitary hyperfunction should be reduced.
Since 1956 we have treated 27 acromegalic patients by the implantation of 90Y or ""Au or by transethmoidal hypophysectomy (Table 1) . Two patients who failed to respond to 9OY implant were subsequently further treated, one by '9"Au-implant (26-2 mCi), the other by transethmoidal hypophysectomy.
The results in these three groups of patients are summarized as follows:
Relief of symptoms: The response of various symptoms in each patient to treatment has been assessed according to a three-point score in which 0= worse, 1= no change, and 2= improvement. The mean for each treatment group is shown in Fig 1. Although improvement of several of the symptoms has occurred in all three groups, transethmoidal hypophysectomy gave generally superior results to either method of implantation.
Reduction of soft tissue change: This has been assessed by serial estimates of hand volumes, by questioning regarding ring, glove, shoe, and denture size and by appearance. Again, improvement in several of these parameters has been noted in all three treatment groups, but convincing evidence of the change of appearance has only been observed in those patients treated by transethmoidal hypophysectomy.
Visual defects: Field defects were present in 3 patients prior to treatment; two were treated by 90Y implant and one by transethmoidal hypophysectomy. Return to full vision occurred in all 3.
Diabetes: Three patients had active diabetes requiring insulin therapy. Two of these patients Growth hormone: The concentration of plasma growth hormone has been estimated by radioimmune assay before and serially after treatment. Most of the patients in the 90Y-implant group were treated prior to the availability of the assay and only post-operative levels are given. In Fig 2 the pre-operative levels (where available) and the lowest post-operative levels are contrasted for each patient in each treatment group. Transeth-moidal hypophysectomy has proved more effective in reducing growth hormone levels than either of the implant procedures.
It is concluded that the implantation of 90Y and/or " 8Au by the methods we use is less effective treatment for acromegaly than surgical removal of the pituitary gland, an operation which can be carried out effectively by the transethmoidal route. However, further time is required to confirm that long-term remission of symptoms and reduction in plasma growth hormone concentration follows this operation.
Cushing's Syndrome Implantation of "'8Au into the pituitary fossa has been used to treat 11 patients with Cushing's disease of pituitary type. Eight of these patients had normal-sized pituitary fossx and primary Cushing's disease, one had an invasive tumour, and 2 patients had previously been treated by adrenalectomy. As pituitary function is only suppressed, and not ablated, by "'8Au implant, maintenance therapy has been required in only one patient. Primary Cushing's disease: Evidence of clinical and biochemical remission of the syndrome has been observed in 5 of 6 assessed patients (Fig 3) . One of these 5 patients had a partial response but the other 4 have experienced complete remission of their syndrome.
The sixth patient had no remission and, as a result, the adrenals were explored seven months after implantation. As that on the left side appeared to contain a benign adenoma, it alone was removed. Remission still has not occurred. Histological examination of the left adrenal Post-adrenalectomy: Two patients have been treated. The first, treated in 1963, had persistent Cushing's syndrome despite a total left and subtotal right adrenalectomy in 1952-53 and radiotherapy (3,250 rads) to the pituitary fossa in 1955. She also was pigmented, had high plasma MSH levels and her sella was enlarged. An implant of 90Y (10 mCi) was performed in January 1963 without improvement. In August a further implant, this time of 198Au (25A4 mCi) was performed. This has led to remission of her syndrome, disappearance of pigmentation and reduction of serum MSH to normal.
The second patient had Cushing's syndrome treated by bilateral subtotal adrenalectomy in 1960. The surgeon noted at that time that her scar was markedly pigmented and in 1962 she developed headache, dense pigmentation, deterioration of vision and enlargement of the sella. Thirty-nine mCi of 198Au were implanted in 1965.
This has resulted in gradual diminution, but not complete disappearance, of pigmentation.
It is concluded that gold implantation of the pituitary can lead to remission in Cushing's syndrome of pituitary type. However, the recent occurrence of visual damage in one patient and paralysis of the III cranial nerve in another, has drawn attention to the danger of implanting gamma-emitting isotopes into the sella turcica even when their activity is carefully controlled. It is our current view that the risks of implanting sources having gamma activity into the pituitary fossa outweigh their therapeutic advantage. Such an isotope should be used only if it can be removed should the calculated dose of radiation to the diaphragma after implantation exceed that originally planned. The use of an after-loading technique would appear a rational development if the long-term results of this small series demonstrate that gamma irradiation of the pituitary is the treatment of choice in Cushing's syndrome of pituitary type.
